94-18776. Findings of Scientific Misconduct

[Federal Register Volume 59, Number 147 (Tuesday, August 2, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-18776]


[[Page Unknown]]

[Federal Register: August 2, 1994]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary
[G N #2259]

 

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:
    Annmarie Surprenant, Ph.D., Glaxo Institute for Molecular Biology. 
An inquiry and investigation conducted by the Oregon Health Sciences 
University (OHSU) found that Annmarie Surprenant, Ph.D., had 
misrepresented her academic credentials in a grant application for 
Public Health Service (PHS) research funds. The OHSU found that Dr. 
Surprenant had falsely stated that she had earned an M.K. degree from 
the University of Illinois at Chicago in 1976. As a result of the OHSU 
investigation, Dr. Surprenant resigned from the OHSU faculty. During 
its oversight review of the OHSU report, the Office of Research 
Integrity (ORI) discovered that Dr. Surprenant had also falsely claimed 
to have earned an M.D. on two additional PHS research grant 
applications. Based upon the OHSU report, as well as the information 
obtained by ORI during its oversight review, ORI found that Dr. 
Surprenant engaged in scientific misconduct by falsely claiming to have 
earned an M.D. in three PHS research grant applications. Dr. Surprenant 
accepted the ORI finding and agreed to a Voluntary Exclusion and 
Settlement Agreement under which she will not apply for Federal grant 
or contract funds and will not serve on PHS advisory committees, 
boards, or peer review groups for a three year period beginning June 8, 
1994.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research 
Investigations Office of Research Integrity 301-443-5330.

    Dated: July 26, 1994.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 94-18776 Filed 8-1-94; 8:45 am]
BILLING CODE 4160-17-M